SANUWAVE Health, Inc. (SNWV)
| Market Cap | 144.89M -37.3% |
| Revenue (ttm) | 44.34M +22.5% |
| Net Income | 16.49M |
| EPS | 0.92 |
| Shares Out | 8.60M |
| PE Ratio | 18.27 |
| Forward PE | 518.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,553 |
| Open | 17.08 |
| Previous Close | 17.07 |
| Day's Range | 16.37 - 17.20 |
| 52-Week Range | 15.36 - 46.59 |
| Beta | 1.36 |
| Analysts | Strong Buy |
| Price Target | 51.00 (+202.67%) |
| Earnings Date | May 12, 2026 |
About SNWV
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and ch... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SNWV stock is "Strong Buy." The 12-month stock price target is $51.0, which is an increase of 202.67% from the latest price.
News
SANUWAVE Health Earnings Call Transcript: Q1 2026
Record Q1 revenue and strong consumables growth were achieved despite a market freeze from CMS pricing changes. Guidance for 2026 remains robust, with expectations for a stronger second half driven by seasonality and large account engagement.
Sanuwave Health reports Q1 EPS (17c) vs (72c) last year
Reports Q1 revenue $9.6M vs $9.3M last year. “The seemingly ubiquitous question in advanced wound care during Q1 was ‘When is the turn coming and when will the recovery start?’”…
Sanuwave Health sees Q2 revenue $11.1M-$11.6M, one estimate $11.5M
17:03 EDT Sanuwave Health (SNWV) sees Q2 revenue $11.1M-$11.6M, one estimate $11.5M
Sanuwave Health backs FY26 revenue view $51M-$55M, one estimate $51.35M
17:03 EDT Sanuwave Health (SNWV) backs FY26 revenue view $51M-$55M, one estimate $51.35M
Sanuwave Announces Revenues and Financial Results for Q1 FY2026
Q1 2026 revenues were $9.6 million , up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results
EDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will h...
Sanuwave Health narrows Q1 revenue view to $9.6M-$9.7M from $9.6M-$10.3M
Q1 revenue consensus $9.84M. “At the end of Q1 the Company saw several good-sized deals (all of which remain live) slide out of the quarter and this brought us in…
Sanuwave Health price target lowered to $47 from $53 at Roth Capital
Roth Capital analyst Kyle Bauser lowered the firm’s price target on Sanuwave Health (SNWV) to $47 from $53 and keeps a Buy rating on the shares. Despite an FY26 revenue…
SANUWAVE Health Earnings Call Transcript: Q4 2025
Record Q4 and full-year revenue growth driven by UltraMIST system sales and consumables, despite industry disruption from CMS reimbursement changes. Strategic channel shift to resellers and strong cash position support 2026 growth outlook of 16%–25%.
Sanuwave Health reports Q4 adjusted EBITDA $4.77M vs $3.66M last year
Reports Q4 revenue $13.4M, up 29.7% year-over-year. “We’re pleased to be, once more, announcing an all-time record quarter for Sanuwave on both revenues and adjusted EBITDA, especially during such cha...
Sanuwave Health sees Q1 revenue $9.6M-$10.3M
17:02 EDT Sanuwave Health (SNWV) sees Q1 revenue $9.6M-$10.3M
Sanuwave Health sees FY26 revenue $51M-$55M
17:03 EDT Sanuwave Health (SNWV) sees FY26 revenue $51M-$55M
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
Q4 2025 revenues were $13.4 million , up 29.7% from Q4 2024. This was an all-time quarterly record for the Company.
Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results
EDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will...
Sanuwave Health sees Q4 revenue $13.3M-$13.4M, up 29%-30% y/y
On Friday, the company stated: “Sanuwave Health (SNWV) announced that revenues for the fourth quarter of 2025 are expected to be in the range of $13.3 to $13.4 million, an…
Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Sanuwave Health Reports Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Roth Capital views Sanuwave Health’s UltraMIST news as ‘highly favorable’
Roth Capital notes Sanuwave Health (SNWV) announced that its UltraMIST product line had been added to Healogics Wound Care Supply’s group purchasing organization, Healogics iSupply. The collaboration ...
Sanuwave Health adds UltraMIST product line to Healogics iSupply
Sanuwave Health (SNWV) announced the addition of its UltraMIST product line to Healogics iSupply. With this expansion, UltraMIST becomes an option for iSupply members, including Wound Care Centers, ho...
Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply
Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 0...
SANUWAVE Health Earnings Call Transcript: Q3 2025
Q3 2025 set new revenue and unit sales records, with 22% year-over-year growth and strong gross margins. Net income swung to $10.3 million, aided by non-cash gains and a patent sale. Guidance for Q4 anticipates continued record growth as reimbursement uncertainty eases.
Sanuwave Health reports Q3 EPS 46c vs. ($6.49) last year
Reports Q3 revenue $11.45M vs. $9.36M last year. “Despite the headwinds in the quarter arising from uncertainty about proposed reimbursement changes to certain wound care modalities, particularly skin...
Sanuwave Announces Q3 FY2025 Financial Results
Q3 2025 revenues were $11.5 million , up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will ...
Sanuwave Health price target lowered to $53 from $55 at Roth Capital
Roth Capital analyst Kyle Bauser lowered the firm’s price target on Sanuwave Health (SNWV) to $53 from $55 and keeps a Buy rating on the shares. The firm cites the…